Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dobarro

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Revista Espanola De Cardiologia (English Ed.)|September 2, 2022
Durable ventricular assist device in Spain (2007-2020). First report of the REGALAD registryManuel Gómez-Bueno, Enrique Pérez de la Sota, Alberto Forteza Gil, et al.
ESC Heart Failure|January 19, 2023
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registryDavid Dobarro, Víctor Donoso-Trenado, Eduard Solé-González, et al.
Life (Basel, Switzerland)|January 8, 2025
Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD RegistriesDavid Dobarro, Sergio Raposeiras-Roubin, Luis Almenar-Bonet, et al.
European Heart Journal|July 15, 2021
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathyLuis R Lopes, Soledad Garcia-Hernández, Massimiliano Lorenzini, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Revista Espanola De Cardiologia (English Ed.)|September 2, 2022
Durable ventricular assist device in Spain (2007-2020). First report of the REGALAD registryManuel Gómez-Bueno, Enrique Pérez de la Sota, Alberto Forteza Gil, et al.
ESC Heart Failure|January 19, 2023
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registryDavid Dobarro, Víctor Donoso-Trenado, Eduard Solé-González, et al.
Life (Basel, Switzerland)|January 8, 2025
Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD RegistriesDavid Dobarro, Sergio Raposeiras-Roubin, Luis Almenar-Bonet, et al.
European Heart Journal|July 15, 2021
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathyLuis R Lopes, Soledad Garcia-Hernández, Massimiliano Lorenzini, et al.
Pageof 6